Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET
Company Participants
Naomi Eichenbaum - Vice President-Investor Relations
Dr. Eric Dube - Chief Executive Officer
Dr. Jula Inrig - Chief Medical Officer
Peter Heerma - Chief Commercial Officer
Chris Cline - Chief Financial Officer
Dr. Bill Rote - Senior Vice President of Research & Development
Conference Call Participants
Anupam Rama - JP Morgan
Maury Raycroft - Jefferies
Greg Harrison - Bank of America
Vamil Divan - Guggenheim Securities
Liisa Bayko - Evercore.ISI
Edwin Delfin - Barclays
Laura Chico - Wedbush Securities
Alex Thompson - Stifel
Allison Bratzel - Piper Sandler
Ed Arce - H.C. Wainwright & Company
Operator
Good day, and welcome to the Travere Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. Today's conference call is being recorded.
At this time, I would like to turn the conference call over to the Vice President of Investor Relations, Naomi Eichenbaum. Please go ahead, Naomi.
Naomi Eichenbaum
Thank you. Good afternoon, and welcome to Travere Therapeutics third quarter 2023 financial results and corporate update call. Thank you all for joining. Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer; Dr. Bill Rote, Senior Vice President of Research and Development will join us for the Q&A session.
Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance and achievements to differ materially from those expressed or implied by the statements.
Please see the forward-looking statement disclaimer on the Company's press release issued earlier today, as well as the Risk Factors section in our Form 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made November 07, 2023 and Travere specifically disclaims any obligation to update such statements to reflect future information, events or circumstances.
With that, let me now turn the call over to Eric. Eric?